An overview of Epstein-Barr virus: From discovery to future directions for treatment and prevention

Herpes

Volumn 7, Issue 3, 2000, Pages 76-82

  Andersson, J ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adoptive therapy; Epstein Barr virus (EBV); Immunity; Immunopathology; Infectious mononucleosis (IM); Lymphoproliferative disorders; Treatment; Vaccine; X linked lymphoproliferative syndrome (XLP)

Indexed keywords

ACICLOVIR; CIDOFOVIR; CITALOPRAM; ETOPOSIDE; FOSCARNET; GAMMA INTERFERON; GANCICLOVIR; IMMUNOGLOBULIN; PODOPHYLLIN; PREDNISOLONE; SEROTONIN ANTAGONIST; VALACICLOVIR;

ADOPTIVE IMMUNOTHERAPY; BONE MARROW TRANSPLANTATION; BURKITT LYMPHOMA; CHEMOPROPHYLAXIS; CLINICAL TRIAL; EPSTEIN BARR VIRUS; HEMOPHAGOCYTIC SYNDROME; HUMAN; IMMUNOPATHOLOGY; INFECTIOUS MONONUCLEOSIS; LYMPHOPROLIFERATIVE DISEASE; NASOPHARYNX CARCINOMA; ORGAN TRANSPLANTATION; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY; VACCINATION; VIRUS INFECTION; VIRUS REACTIVATION;

EID: 0033764494     PISSN: 09697667     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. A lymphoma syndrome in tropical Africa
2. Morphological and biological studies on a virus in cultured lymphoblasts from Burkitt's lymphoma
3. Transformation of fetal human leukocytes in vitro by filtrates of human leukemic cell line containing herpes like virus
4. Detection of Epstein-Barr virus DNA in human tumors
5. Relation of Burkitt's tumor-associated herpes-type virus to infectious mononucleosis
6. Primary infection with Epstein-Barr virus in infants in the United States: Clinical and serologic observations
7. Clinical and immunological considerations in Epstein-Barr virus-associated diseases
8. The complexity of the Epstein-Barr virus infection in humans
9. Epstein-Barr virus
10. Determination of the role of CD21 during Epstein-Barr virus infection of B-lymphoblastoid cells
11. Epstein-Barr virus (EBV) infection in infectious mononucleosis: Virus latency, replication and phenotype of EBV-infected cells
12. Epstein-Barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood immunosuppressed patients
13. EBV persistence in memory B cells in vivo
14. Acute HIV infection among patients tested for mononucleosis
15. Heterophil-negative mononucleosis-like illnesses with atypical lymphocytosis in patients undergoing seroconversions to the human immunodeficiency virus
16. Epstein-Barr virus infection and its role in the expanding spectrum of human diseases
17. Airway obstruction in children with infectious mononucleosis
18. Epstein-Barr virus-associated hemophagocytic syndrome and fatal infectious mononucleosis
19. Severe neurological complications in association with Epstein-Barr virus infection
20. Evaluation of three commercial enzyme-linked immunosorbent assays and two latex agglutination assays for diagnosis of primary Epstein-Barr virus infection
21. Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection
22. Atypical lymphocytes in acute infectious mononucleosis. Identification by multiple T and B lymphocyte markers
23. Detection and quantification of cell-free Epstein-Barr virus by polymerase chain reaction and subsequent DNA enzyme immunoassay
24. Epstein-Barr virus-specific immune defects in patients with persistent symptoms following infectious mononucleosis
25. Polyclonal Ig production after Epstein-Barr virus infection of human lymphocytes in vitro
26. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo
27. Major expansions of selected CD8+ subsets in acute Epstein-Barr virus infection comparison with chronic human immunodeficiency virus disease
28. Extracellular granzymes A and B in humans: Detection of native species during CTL responses in vitro and in vivo
29. Acyclovir for treatment of infectious mononucleosis: A meta-analysis
30. Acyclovir and prednisolone treatment of acute infectious mononucleosis: A multicenter, double-blind, placebo-controlled study
31. Therapeutic potential of cidofovir (HPMPC, Vistide) for the treatment of DNA virus (i.e. herpes-, papova-, pox- and adenovirus) infections
32. Intravenous immunoglobulin therapy in thrombocytopenic infectious mononucleosis
33. Chronic fatigue syndrome: Possible effective treatment with nifedipine
34. X-linked lymphoproliferative syndrome registry report
35. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene
36. X-linked lymphoproliferative disease (XLP) as a model of Epstein-Barr virus-induced immunopathology
37. The potential of adoptive transfer of immunity for reducing post transplant Epstein-Barr virus-associated disease
38. Cure of X-linked lymphoproliferative disease (XLP) with allogeneic hematopoietic stem cell transplantation (HSCT): Report from the XLP registry
39. Epstein-Barr virus-associated hemophagocytic syndrome: Virological and immunopathological studies
40. Hemophagocytic syndrome in Epstein-Barr virus-associated T-lymphoproliferative disorders: Disease spectrum, pathogenesis, and management
41. Detection of Epstein-Barr virus (EBV) genomes in the serum of patients with EBV-associated Hodgkin's disease
42. Nasopharyngeal carcinoma. IX. Antibodies to EBNA and correlation with response to other EBV antigens in Chinese patients
43. Comparative studies on immunity to EBV-associated antigens in NPC patients in North America, Tunisia, France and Hong Kong
44. Expression of an Epstein-Barr virus receptor and Epstein-Barr virus-dependent transformation of human nasopharyngeal epithelial cells
45. Prognostic value of EBV markers in the clinical management of nasopharyngeal carcinoma (NPC): A multicenter follow-up study
46. The Epstein-Barr virus in the pathogenesis of post-transplant lymphoproliferative disorders. Clinical, pathologic, and virologic correlation
47. Epstein-Barr virus-related disorderin children undergoing renal transplantation with facrolimus-based immunosupression
48. Epstein-Barr virus DNA in peripheral blood leukocytes of patients with posttransplant lymphoprol ferative disease
49. Epstein-Barr virus infection in sixty pediatric liver graft recipients: Diagnosis of primary infection and virologic follow-up
50. The management of Epstein-Barr virus associated post-transplant lymphoproliferative disorders in pediatric solid-organ transplant recipients
51. Post-transplantation lymphoproliferative disease
52. Treatment of post-transplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes
53. Activation and adoptive transfer of Epstein-Barr virus specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease
54. Immunotherapy for Epstein-Barr virus associated cancers
55. Anti-F-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: Prognostic factors and long-term outcome
56. Vaccine strategies against Epstein-Barr virus-associated diseases: Lessons from studies on cytotoxic T-cell-mediated immune regulation
57. EBV structural antigens, gp350 and gp85, as targets for ex vivo virus-specific CTL during acute infectious mononucleosis: Potential use of gp350/gp85 CTL epitopes for vaccine design